메뉴 건너뛰기




Volumn 27, Issue 7, 2014, Pages 1028-1034

BRAF V600E-specific immunohistochemistry reveals low mutation rates in biliary tract cancer and restriction to intrahepatic cholangiocarcinoma

Author keywords

biliary tract cancer; BRAF; cholangiocarcinoma; immunohistochemistry; V600E; VE1

Indexed keywords

BIOLOGICAL MARKER; B RAF KINASE; BRAF PROTEIN, HUMAN;

EID: 84903763435     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2013.206     Document Type: Article
Times cited : (99)

References (38)
  • 2
    • 77955285782 scopus 로고    scopus 로고
    • Genetics of biliary tract cancers and emerging targeted therapies
    • Hezel AF, Deshpande V, Zhu AX. Genetics of biliary tract cancers and emerging targeted therapies. J Clin Oncol 2010;28: 3531-3540
    • (2010) J Clin Oncol , vol.28 , pp. 3531-3540
    • Hezel, A.F.1    Deshpande, V.2    Zhu, A.X.3
  • 3
    • 79954441895 scopus 로고    scopus 로고
    • Analysis of BRAF V600E mutation in 1, 320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma
    • Schindler G, Capper D, Meyer J, et al. Analysis of BRAF V600E mutation in 1, 320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma. Acta Neuropathol 2011;121: 397-405
    • (2011) Acta Neuropathol , vol.121 , pp. 397-405
    • Schindler, G.1    Capper, D.2    Meyer, J.3
  • 4
    • 38949131824 scopus 로고    scopus 로고
    • BRAF (E600) in benign and malignant human tumours
    • Michaloglou C, Vredeveld LC, Mooi WJ, et al. BRAF(E600) in benign and malignant human tumours. Oncogene 2008;27: 877-895
    • (2008) Oncogene , vol.27 , pp. 877-895
    • Michaloglou, C.1    Vredeveld, L.C.2    Mooi, W.J.3
  • 5
    • 18444374405 scopus 로고    scopus 로고
    • Mutations of the BRAF gene in human cancer
    • Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature 2002;417: 949-954
    • (2002) Nature , vol.417 , pp. 949-954
    • Davies, H.1    Bignell, G.R.2    Cox, C.3
  • 6
    • 79551595779 scopus 로고    scopus 로고
    • Targeting BRAF for patients with melanoma
    • Arkenau HT, Kefford R, Long GV. Targeting BRAF for patients with melanoma. Br J Cancer 2011;104: 392-398
    • (2011) Br J Cancer , vol.104 , pp. 392-398
    • Arkenau, H.T.1    Kefford, R.2    Long, G.V.3
  • 7
    • 77956030786 scopus 로고    scopus 로고
    • Inhibition of mutated, activated BRAF in metastatic melanoma
    • Flaherty KT, Puzanov I, Kim KB, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010;363: 809-819
    • (2010) N Engl J Med , vol.363 , pp. 809-819
    • Flaherty, K.T.1    Puzanov, I.2    Kim, K.B.3
  • 8
    • 79959795786 scopus 로고    scopus 로고
    • Improved survival with vemurafenib in melanoma with BRAF V600E mutation
    • Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011;364: 2507-2516
    • (2011) N Engl J Med , vol.364 , pp. 2507-2516
    • Chapman, P.B.1    Hauschild, A.2    Robert, C.3
  • 9
    • 84864285704 scopus 로고    scopus 로고
    • Dabrafenib in BRAF-mutated metastatic melanoma: A multicentre, open-label, phase 3 randomised controlled trial
    • Hauschild A, Grob JJ, Demidov LV, et al. Dabrafenib in BRAF-mutated metastatic melanoma: A multicentre, open-label, phase 3 randomised controlled trial. Lancet 2012;380: 358-365
    • (2012) Lancet , vol.380 , pp. 358-365
    • Hauschild, A.1    Grob, J.J.2    Demidov, L.V.3
  • 10
    • 84876098212 scopus 로고    scopus 로고
    • Brainstem ganglioglioma successfully treated with vemurafenib
    • Rush S, Foreman N, Liu A. Brainstem ganglioglioma successfully treated with vemurafenib. J Clin Oncol 2013;31: E159-e160
    • (2013) J Clin Oncol , vol.31
    • Rush, S.1    Foreman, N.2    Liu, A.3
  • 11
    • 84879177690 scopus 로고    scopus 로고
    • Clinical responses to vemurafenib in patients with metastatic papillary thyroid cancer harboring V600EBRAF mutation
    • Kim K, Cabanillas M, Lazar AJ, et al. Clinical responses to vemurafenib in patients with metastatic papillary thyroid cancer harboring V600EBRAF mutation. Thyroid 2013;23: 1277-1283
    • (2013) Thyroid , vol.23 , pp. 1277-1283
    • Kim, K.1    Cabanillas, M.2    Lazar, A.J.3
  • 12
    • 84861083983 scopus 로고    scopus 로고
    • Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: A phase 1 dose-escalation trial
    • Falchook GS, Long GV, Kurzrock R, et al. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: A phase 1 dose-escalation trial. Lancet 2012;379: 1893-1901
    • (2012) Lancet , vol.379 , pp. 1893-1901
    • Falchook, G.S.1    Long, G.V.2    Kurzrock, R.3
  • 13
    • 84861417677 scopus 로고    scopus 로고
    • BRAF inhibition in refractory hairy-cell leukemia
    • Dietrich S, Glimm H, Andrulis M, et al. BRAF inhibition in refractory hairy-cell leukemia. N Engl J Med 2012;366: 2038-2040
    • (2012) N Engl J Med , vol.366 , pp. 2038-2040
    • Dietrich, S.1    Glimm, H.2    Andrulis, M.3
  • 14
    • 84881490568 scopus 로고    scopus 로고
    • Targeting the BRAF V600E mutation in multiple myeloma
    • Andrulis M, Lehners N, Capper D, et al. Targeting the BRAF V600E mutation in multiple myeloma. Cancer Discov 2013;3: 862-869
    • (2013) Cancer Discov , vol.3 , pp. 862-869
    • Andrulis, M.1    Lehners, N.2    Capper, D.3
  • 15
    • 84865001178 scopus 로고    scopus 로고
    • Detection of braf v600e mutations in skin metastases of malignant melanoma by monoclonal antibody ve1
    • Skorokhod A, Capper D, von Deimling A, et al. Detection of BRAF V600E mutations in skin metastases of malignant melanoma by monoclonal antibody VE1. J Am Acad Dermatol 2012;67: 488-491
    • (2012) J Am Acad Dermatol , vol.67 , pp. 488-491
    • Skorokhod, A.1    Capper, D.2    Von Deimling, A.3
  • 16
    • 84871619722 scopus 로고    scopus 로고
    • Immunohistochemistry is highly sensitive and specific for the detection of V600E BRAF mutation in melanoma
    • Long GV, Wilmott JS, Capper D, et al. Immunohistochemistry is highly sensitive and specific for the detection of V600E BRAF mutation in melanoma. Am J Surg Pathol 2013;37: 61-65
    • (2013) Am J Surg Pathol , vol.37 , pp. 61-65
    • Long, G.V.1    Wilmott, J.S.2    Capper, D.3
  • 17
    • 84875410796 scopus 로고    scopus 로고
    • Detection of braf pV600E mutations in melanomas: Comparison of four methods argues for sequential use of immunohistochemistry and pyrosequencing
    • Colomba E, Helias-Rodzewicz Z, Von Deimling A, et al. Detection of BRAF p.V600E mutations in melanomas: Comparison of four methods argues for sequential use of immunohistochemistry and pyrosequencing. J Mol Diagn 2013;15: 94-100
    • (2013) J Mol Diagn , vol.15 , pp. 94-100
    • Colomba, E.1    Helias-Rodzewicz, Z.2    Von Deimling, A.3
  • 18
    • 84880587203 scopus 로고    scopus 로고
    • A role for immunohistochemical detection of BRAF V600E prior to BRAF-inhibitor treatment of malignant melanoma
    • Lade-Keller J, Kristensen LS, Riber-Hansen R, et al. A role for immunohistochemical detection of BRAF V600E prior to BRAF-inhibitor treatment of malignant melanomä J Clin Pathol 2013;66: 723-725
    • (2013) J Clin Pathol , vol.66 , pp. 723-725
    • Lade-Keller, J.1    Kristensen, L.S.2    Riber-Hansen, R.3
  • 19
    • 84873993511 scopus 로고    scopus 로고
    • Immunohistochemical analysis of BRAF(V600E) expression of primary and metastatic melanoma and comparison with mutation status and melanocyte differentiation antigens of metastatic lesions
    • Busam KJ, Hedvat C, Pulitzer M, et al. Immunohistochemical analysis of BRAF(V600E) expression of primary and metastatic melanoma and comparison with mutation status and melanocyte differentiation antigens of metastatic lesions. Am J Surg Pathol 2013; 37: 413-420
    • (2013) Am J Surg Pathol , vol.37 , pp. 413-420
    • Busam, K.J.1    Hedvat, C.2    Pulitzer, M.3
  • 20
    • 84862109270 scopus 로고    scopus 로고
    • Immunohistochemical detection of the BRAF V600E-mutated protein in papillary thyroid carcinoma
    • Koperek O, Kornauth C, Capper D, et al. Immunohistochemical detection of the BRAF V600E-mutated protein in papillary thyroid carcinoma. Am J Surg Pathol 2012;36: 844-850
    • (2012) Am J Surg Pathol , vol.36 , pp. 844-850
    • Koperek, O.1    Kornauth, C.2    Capper, D.3
  • 21
    • 84869220840 scopus 로고    scopus 로고
    • Utilization of a MAB for BRAF(V600E) detection in papillary thyroid carcinoma
    • Bullock M, O'Neill C, Chou A, et al. Utilization of a MAB for BRAF(V600E) detection in papillary thyroid carcinoma. Endocr Relat Cancer 2012;19: 779-784
    • (2012) Endocr Relat Cancer , vol.19 , pp. 779-784
    • Bullock, M.1    O'Neill, C.2    Chou, A.3
  • 22
    • 84884513645 scopus 로고    scopus 로고
    • BRAFV600E immunohistochemistry facilitates universal screening of colorectal cancers for Lynch Syndrome
    • Toon CW, Walsh MD, Chou A, et al. BRAFV600E immunohistochemistry facilitates universal screening of colorectal cancers for Lynch Syndrome. Am J Surg Pathol 2013;37: 1592-1602
    • (2013) Am J Surg Pathol , vol.37 , pp. 1592-1602
    • Toon, C.W.1    Walsh, M.D.2    Chou, A.3
  • 23
    • 84880265173 scopus 로고    scopus 로고
    • BRAF V600Especific immunohistochemistry for the exclusion of Lynch syndrome in MSI-H colorectal cancer
    • Capper D, Voigt A, Bozukova G, et al. BRAF V600Especific immunohistochemistry for the exclusion of Lynch syndrome in MSI-H colorectal cancer. Int J Cancer 2013;133: 1624-1630
    • (2013) Int J Cancer , vol.133 , pp. 1624-1630
    • Capper, D.1    Voigt, A.2    Bozukova, G.3
  • 24
    • 84878608078 scopus 로고    scopus 로고
    • Mutant BRAF V600E protein in ganglioglioma is predominantly expressed by neuronal tumor cells
    • Koelsche C, Wohrer A, Jeibmann A, et al. Mutant BRAF V600E protein in ganglioglioma is predominantly expressed by neuronal tumor cells. Acta Neuropathol 2013;125: 891-900
    • (2013) Acta Neuropathol , vol.125 , pp. 891-900
    • Koelsche, C.1    Wohrer, A.2    Jeibmann, A.3
  • 25
    • 84870067191 scopus 로고    scopus 로고
    • Application of a BRAF V600E mutation-specific antibody for the diagnosis of hairy cell leukemia
    • Andrulis M, Penzel R, Weichert W, et al. Application of a BRAF V600E mutation-specific antibody for the diagnosis of hairy cell leukemia. Am J Surg Pathol 2012;36: 1796-1800
    • (2012) Am J Surg Pathol , vol.36 , pp. 1796-1800
    • Andrulis, M.1    Penzel, R.2    Weichert, W.3
  • 26
    • 84879224082 scopus 로고    scopus 로고
    • Molecular profiling of cholangiocarcinoma shows potential for targeted therapy treatment decisions
    • Voss JS, Holtegaard LM, Kerr SE, et al. Molecular profiling of cholangiocarcinoma shows potential for targeted therapy treatment decisions. Hum Pathol 2013;44: 1216-1222
    • (2013) Hum Pathol , vol.44 , pp. 1216-1222
    • Voss, J.S.1    Holtegaard, L.M.2    Kerr, S.E.3
  • 27
    • 84875244110 scopus 로고    scopus 로고
    • Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes
    • Sia D, Hoshida Y, Villanueva A, et al. Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes. Gastroenterology 2013;144: 829-840
    • (2013) Gastroenterology , vol.144 , pp. 829-840
    • Sia, D.1    Hoshida, Y.2    Villanueva, A.3
  • 28
    • 84859441690 scopus 로고    scopus 로고
    • Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors
    • Andersen JB, Spee B, Blechacz BR, et al. Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors. Gastroenterology 2012;142: E15
    • (2012) Gastroenterology , vol.142
    • Andersen, J.B.1    Spee, B.2    Blechacz, B.R.3
  • 29
    • 0037624602 scopus 로고    scopus 로고
    • Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma
    • Tannapfel A, Sommerer F, Benicke M, et al. Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma. Gut 2003;52: 706-712
    • (2003) Gut , vol.52 , pp. 706-712
    • Tannapfel, A.1    Sommerer, F.2    Benicke, M.3
  • 30
    • 4544385478 scopus 로고    scopus 로고
    • Mutational analysis of BRAF in gallbladder carcinomas in association with K-ras and p53 mutations and microsatellite instability
    • Saetta AA, Papanastasiou P, Michalopoulos NV, et al. Mutational analysis of BRAF in gallbladder carcinomas in association with K-ras and p53 mutations and microsatellite instability. Virchows Arch 2004;445: 179-182
    • (2004) Virchows Arch , vol.445 , pp. 179-182
    • Saetta, A.A.1    Papanastasiou, P.2    Michalopoulos, N.V.3
  • 31
    • 8144225290 scopus 로고    scopus 로고
    • The V599E BRAF mutation is uncommon in biliary tract cancers
    • Goldenberg D, Rosenbaum E, Argani P, et al. The V599E BRAF mutation is uncommon in biliary tract cancers. Mod Pathol 2004;17: 1386-1391
    • (2004) Mod Pathol , vol.17 , pp. 1386-1391
    • Goldenberg, D.1    Rosenbaum, E.2    Argani, P.3
  • 32
    • 84856298658 scopus 로고    scopus 로고
    • Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broadbased tumor genotyping
    • Borger DR, Tanabe KK, Fan KC, et al. Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broadbased tumor genotyping. Oncologist 2012;17: 72-79
    • (2012) Oncologist , vol.17 , pp. 72-79
    • Borger, D.R.1    Tanabe, K.K.2    Fan, K.C.3
  • 33
    • 84875952085 scopus 로고    scopus 로고
    • Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer
    • Xing M, Alzahrani AS, Carson KA, et al. Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer. JAMA 2013;309: 1493-1501
    • (2013) JAMA , vol.309 , pp. 1493-1501
    • Xing, M.1    Alzahrani, A.S.2    Carson, K.A.3
  • 34
    • 84978034236 scopus 로고    scopus 로고
    • Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma
    • Long GV, Menzies AM, Nagrial AM, et al. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J Clin Oncol 2011;29: 1239-1246
    • (2011) J Clin Oncol , vol.29 , pp. 1239-1246
    • Long, G.V.1    Menzies, A.M.2    Nagrial, A.M.3
  • 35
    • 84874581453 scopus 로고    scopus 로고
    • Diagnostic value of immunohistochemistry for the detection of the BRAFV600E mutation in primary lung adenocarcinoma Caucasian patients
    • Ilie M, Long E, Hofman V, et al. Diagnostic value of immunohistochemistry for the detection of the BRAFV600E mutation in primary lung adenocarcinoma Caucasian patients. Ann Oncol 2013;24: 742-748
    • (2013) Ann Oncol , vol.24 , pp. 742-748
    • Ilie, M.1    Long, E.2    Hofman, V.3
  • 36
    • 84857030136 scopus 로고    scopus 로고
    • Immunohistochemical testing of BRAF V600E status in 1, 120 tumor tissue samples of patients with brain metastases
    • Capper D, Berghoff AS, Magerle M, et al. Immunohistochemical testing of BRAF V600E status in 1, 120 tumor tissue samples of patients with brain metastases. Acta Neuropathol 2012;123: 223-233
    • (2012) Acta Neuropathol , vol.123 , pp. 223-233
    • Capper, D.1    Berghoff, A.S.2    Magerle, M.3
  • 37
    • 84868120907 scopus 로고    scopus 로고
    • Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): A multicentre, open-label, phase 2 trial
    • Long GV, Trefzer U, Davies MA, et al. Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): A multicentre, open-label, phase 2 trial. Lancet Oncol 2012;13: 1087-1095
    • (2012) Lancet Oncol , vol.13 , pp. 1087-1095
    • Long, G.V.1    Trefzer, U.2    Davies, M.A.3
  • 38
    • 84872122524 scopus 로고    scopus 로고
    • Effect of dabrafenib on melanoma cell lines harbouring the BRAF(V600D/R) mutations
    • Gentilcore G, Madonna G, Mozzillo N, et al. Effect of dabrafenib on melanoma cell lines harbouring the BRAF(V600D/R) mutations. BMC Cancer 2013;13: 17
    • (2013) BMC Cancer , vol.13 , pp. 17
    • Gentilcore, G.1    Madonna, G.2    Mozzillo, N.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.